MCM
LGND icon

Matarin Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Matarin Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-54,157
Closed -$4.58M – 277
2018
Q4 		$4.58M Sell
54,157
-9,243
-15% -$985K 0.37% 98
2018
Q3 		$10.9M Sell
63,400
-2,645
-4% -$399K 0.7% 58
2018
Q2 		$8.54M Sell
66,045
-8,823
-12% -$985K 0.62% 66
2018
Q1 		$7.71M Sell
74,868
-1,534
-2% -$152K 0.58% 65
2017
Q4 		$6.53M Buy
76,402
+33,398
+78% +$2.89M 0.51% 70
2017
Q3 		$3.65M Buy
43,004
+18,677
+77% +$1.48M 0.31% 130
2017
Q2 		$1.84M Sell
24,327
-39,463
-62% -$2.76M 0.17% 159
2017
Q1 		$4.21M Sell
63,790
-17,838
-22% -$1.17M 0.41% 89
2016
Q4 		$5.17M Sell
81,628
-26,764
-25% -$1.69M 0.58% 55
2016
Q3 		$6.9M Buy
108,392
+4,827
+5% +$354K 0.76% 41
2016
Q2 		$7.71M Buy
103,565
+46,803
+82% +$3.47M 1.05% 12
2016
Q1 		$3.79M Buy
56,762
+27,733
+96% +$1.69M 0.53% 81
2015
Q4 		$1.96M Buy
29,029
+24,159
+496% +$1.49M 0.29% 130
2015
Q3 		$260K Buy
+4,870
New +$295K 0.05% 201
2014
Q3 		– Sell
-25,167
Closed -$978K – 176
2014
Q2 		$978K Buy
25,167
+7,749
+44% +$314K 0.44% 106
2014
Q1 		$731K Sell
17,418
-199
-1% -$8.29K 0.43% 86
2013
Q4 		$578K Buy
+17,617
New +$574K 0.36% 98

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Matarin Capital Management's LGND Position: Q1 2019 in Review

Matarin Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 54,157 shares — an estimated $4.58M sold.

Matarin Capital Management first reported a position in LGND in Q4 2013 and held it in 17 quarters. The position peaked at $10.9M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Matarin Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Matarin Capital Management sold 54,157 Ligand Pharmaceuticals shares in Q1 2019, an estimated $4.58M.
  • Matarin Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 17 quarters.
  • Matarin Capital Management's Ligand Pharmaceuticals position peaked at $10.9M in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Matarin Capital Management's 13F filing for Q1 2019, filed 24 Apr 2019.